Research graph
References from Defining value criteria for outcomes-based managed entry agreements in CAR-T therapy for relapsed/refractory multiple myeloma: a multi-criteria decision analysis study. Local targets link to admitted publications; unresolved targets remain external evidence.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
10.1016/s1470-2045(14)70442-5 · 2014 · External reference
Pathobiology and diagnosis of multiple myeloma
10.1016/j.soncn.2017.05.012 · 2017 · External reference
Current health state affected patient preferences more than disease status: a discrete choice experiment in multiple myeloma
10.1016/j.jval.2023.01.016 · 2023 · External reference
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
10.1038/s41375-022-01531-2 · 2022 · External reference
Characterization and outcomes of Spanish patients with relapsed/refractory multiple myeloma included in the LocoMMotion study
10.1016/j.clml.2023.12.001 · 2024 · External reference
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
10.1186/s13045-023-01479-5 · 2023 · External reference
Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
10.3389/fimmu.2022.991092 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care, PVd or DPd, in lenalidomide-refractory multiple myeloma
2023 · External reference
Unresolved reference
2024 · External reference
Managed entry agreements: policy analysis from the European perspective
10.1016/j.jval.2019.12.008 · 2020 · External reference
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
10.1007/s10198-018-1007-x · 2019 · External reference
Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe
10.18609/cgti.2020.111 · 2020 · External reference
Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology?
2023 · External reference
Financial characteristics of outcomes-based agreements: what do Canadian public payers and pharmaceutical manufacturers prefer?
10.1016/j.jval.2023.12.011 · 2024 · External reference
Solving the problem of financing one-time treatments with evidence uncertainty: which types of outcomes-based payment models could work best for novel CAR-T therapies in multiple myeloma? A systematic review of the published literature
10.18609/cgti.2021.104 · 2021 · External reference
Multiple criteria decision analysis for health care decision making—an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force
10.1016/j.jval.2015.12.003 · 2016 · External reference
Evidence and value: impact on decision making—the EVIDEM framework and potential applications
10.1186/1472-6963-8-270 · 2008 · External reference
How to use the nominal group and Delphi techniques
2016 · External reference
The nominal group technique: a useful consensus methodology in physiotherapy research
2004 · External reference
Using nominal group technique to investigate the views of people with intellectual disabilities on end-of-life care provision
10.1111/j.1365-2648.2007.04227.x · 2007 · External reference
Development of a multicriteria decision analysis framework for evaluating and positioning oncologic treatments in clinical practice
10.1200/jop.19.00487 · 2020 · External reference
Appraising the holistic value of lenvatinib for radioiodine-refractory differentiated thyroid cancer: a multicountry study applying pragmatic MCDA
10.1186/s12885-017-3258-9 · 2017 · External reference
Establishing the cost of implementing a performance-based managed entry agreement for a hypothetical CAR T-cell therapy
10.1080/20016689.2018.1511679 · 2018 · External reference
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
10.1080/20016689.2020.1715536 · 2020 · External reference
The use of innovative payment mechanisms for gene therapies in Europe and the USA
10.2217/rme-2020-0169 · 2021 · External reference
Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force
10.1016/j.jval.2015.12.016 · 2016 · External reference
Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients
10.1186/1478-7547-8-4 · 2010 · External reference
Elotuzumab, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: final overall survival results from the phase 3 randomized ELOQUENT-2 study
10.1038/s41408-020-00357-4 · 2020 · External reference
Stratification for relapsed/refractory multiple myeloma and risk-adapted therapy: sequencing of therapies in relapsed/refractory multiple myeloma
10.3390/cancers13235886 · 2021 · External reference
Unresolved reference
External reference
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
10.2217/fon-2021-1090 · 2022 · External reference
